Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

DRUG2 trials

Sponsors

Novartis Pharma AG

Conditions

Spinal Muscular Atrophy

Phase 3

A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101

Active, not recruitingCTIS2024-513086-39-00

Novartis Pharma AGSpinal Muscular Atrophy

Start: 2020-06-16Target: 22Updated: 2025-12-19

Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials

Active, not recruitingCTIS2024-511707-42-00

Novartis Pharma AGSpinal Muscular Atrophy

Start: 2023-01-05Target: 26Updated: 2025-06-03